



Integra LifeSciences Will Feature the CUSA EXcel+ Ultrasonic Tissue Ablation System At the American Association of Neurological Surgeons Annual Meeting

PLAINSBORO, N.J., Apr 30, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) will showcase its new CUSA EXcel(R)+ ultrasonic tissue ablation system at the 2009 American Association of Neurological Surgeons (AANS) meeting in San Diego, California, May 2-6, 2009. It will be featured at the Practical and Technical Aspects of Transsphenoidal Surgery course, preceding the meeting on May 2, and prominently displayed at Integra's booth for hands-on demonstration throughout the meeting.

The CUSA(R) systems are well recognized medical devices used in neurosurgical and other surgical procedures for the controlled and selective removal of soft tissues that are near critical structures. The CUSA(R) system may also be used for delicate bone sculpting procedures. The CUSA EXcel(R)+ system is designed to maintain clinical performance, while minimizing noise and maximizing durability.

"The CUSA EXcel(R)+ system has many standard features that provide an excellent level of precision and confidence. These include a simple user interface for easy set up in the operating room, a powerful integrated aspiration system, and specific functions to maximize system performance in laparoscopic applications," said Christopher von Jako, Vice President of Marketing for Integra NeuroSciences.

The CUSA EXcel(R)+ system's features include TissueSelect(TM), which provides surgeons with advanced control of tissue fragmentation for tumor removal; and the CUSA(R) Electrosurgery Module (CEM(TM)), which is unique to the CUSA EXcel(R) system and provides simultaneous electrosurgical and ultrasonic capabilities with a press of a button. CEM(TM) provides more complete surgical control of hemostasis and reduces the amount of surgical equipment required for a procedure.

The CUSA EXcel(R)+ system also includes the TipSelect(TM) feature, which enables customization of the handpiece for each procedure. It supports a 23 kHz magnetostrictive handpiece that provides the power required to fragment tough fibrous and calcified tissues. The CUSA EXcel(R)+ system also includes the 36 kHz handpiece, which, at more moderate power levels, is used for procedures that require precision, tactile feedback and delicate control. A variety of specialty tips have also been developed for each handpiece for applications such as tumor removal, liver resection and bone sculpting applications.

Over 2,000 centers worldwide rely on CUSA(R) ultrasonic surgical ablation technology for a variety of procedures, including the removal of brain and abdominal tumors. Integra currently offers a diverse line of CUSA(R) tissue ablation products, including the CUSA NXT, CUSA EXcel(R)+ CUSA EXcel(R), CUSA Selector(R), and CUSA(R) Dissectron(R) systems. The Integra NeuroSciences sales organization sells the CUSA(R) systems. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related neurocritical care. The Integra NeuroSciences direct sales force is the largest neurosurgical sales force in the United States. Integra also has direct sales channels in Europe, Canada, Australia, and New Zealand. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

Gianna Sabella, Director of Corporate Communications

(609) 936-2389

gsabella@integra-LS.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX